Erratum to: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock

Table 2 Serious bleeding rates in clinical trials of drotrecogin alfa (activated)

| Study     | Placebo n (%) | DAA n (%) | P     |
|-----------|---------------|-----------|-------|
| PROWESS   | 17 (2.0)      | 30 (3.5)  | 0.06  |
| PROWESS (CNS) | 1 (0.1)      | 2 (0.2)   | NS    |
| ADDRESS   | 28 (2.2)      | 51 (3.9)  | 0.01  |
| ADDRESS (Day 0–6) | 15 (1.2) | 31 (2.4)  | 0.02  |
| ADDRESS (CNS) | 5 (0.4)      | 6 (0.5)   | 0.72  |
| RESOLVE   | 16 (6.8)      | 16 (6.7)  | 0.97  |
| RESOLVE (Day 0–6) | 8 (3.4)      | 9 (3.8)   | 0.83  |
| RESOLVE (CNS) | 5 (2.1)      | 11 (4.6)  | 0.13  |
| ENHANCE   | –             | 155 (6.5) | –     |

Day 0–6: any serious bleeding event occurring during the DAA infusion period
CNS central nervous system bleeding